Malaysian Genomics CEO Sasha Nordin
PETALING JAYA: Malaysian Genomics Resource Centre Bhd
(Malaysian Genomics) has entered into a strategic cooperation agreement (SCA) with Toticell Limited for the distribution of the group’s products in Bangladesh.
Toticell, which is based in Dhaka, Bangladesh, specialises in regenerative healthcare focusing on treatments for musculoskeletal conditions such as arthritis, sports-related injuries and tendinopathies.
The genomics and biopharmaceutical specialist, in a statement, said under the SCA, the parties agree to cooperate in the distribution of Malaysian Genomics’ cosmeceutical products, genetic screening tests, CAR T-cell therapy services, and other areas of mutual commercial interests.
Malaysian Genomics chief executive officer Sasha Nordin said Bangladesh represents a market with vast opportunities given its population of approximately 165 million people.
“The country’s economy, which is the second-largest in South Asia, is growing rapidly it is identified by Goldman Sachs Inc. as one of the Next Eleven, along with the BRICS economies for potential. Malaysian Genomics is delighted to cooperate with Toticell to bring our products and services to Bangladesh.”
Malaysian Genomics executive director Azri Azerai said: “This collaboration with Toticell falls in line with Malaysian Genomics’ strategic expansion plan which includes diversifying geographically and globally.”
